Lycanumab Shows Promising Results in Early Clinical Trials

2min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

A drug called Lycanumab has shown some promising results in a trial of whether or not it can hold back the ravages of Alzheimer's disease. The makers of the drug conducted a trial on about 1700 participants, and they were crucially in the early stages of Alzheimer's. Results have just been published showing that after taking this drug for 18 months, it had slowed the progression of a group of symptoms by about a quarter.

The Chinese leader who took over a squabbling party following the Tiananmen Square massacre surprised the world by stifling dissent, overseeing a staggering economic awakening—and occasionally breaking into song. We examine the lessons to be drawn from his legacy. After scores of failures, a new Alzheimer’s treatment shows real promise. And our annual ranking of the world’s most expensive cities.

Help us make the show better: take our listener survey at http://economist.com/intelligencesurvey. For full access to print, digital and audio editions of The Economist, subscribe here www.economist.com/intelligenceoffer